Help Desk
860-305-6955
860-305-6955
Providing a pathway to potent pain therapy without risk of addiction and serious side effects
Empowering patients and providers with a safer choice in the fight against pain and addiction.
Potent, safe, and non-addictive—because no one should have to choose between pain and risk.
At Phoenix Pharma Labs, we leverage cutting-edge technologies to enhance the development, manufacturing, and distribution of our pharmaceutical products. Our commitment to innovation ensures that we consistently deliver safe, effective, and high-quality solutions to meet the evolving needs of the healthcare industry.
Our lead candidate for acute & chronic pain: PPL- 138, represents a novel new class of analgesics with robust preclinical validation of potent pain relief (100X potency of morphine), low risk of abuse/addiction, and no respiratory depression.
Our second drug candidate, PPL-103, shows strong potential for treating addiction and pain. It has proven to have a low risk of abuse/addiction and reduced opioid side effects, offering a safer alternative for pain management.
We are advancing PPL-138 into Phase I human clinical trials by year end 2023.
More than $23 M has been raised to date from grants from the U.S. Army and NIH/NIDA, equity investment and investment in kind.
We are a purpose-driven drug development company, deeply committed to transforming lives through the creation of potent, safe, and non-addictive painkillers. Our focus extends to developing thoughtful, science-backed therapies for those navigating pain, addiction, and PTSD—conditions that impact billions of lives.
Moderate/ Severe Pain: PPL- 138 provides potent pain relief for acute & chronic pain, (100X potency of morphine), low risk of abuse/addiction, no respiratory depression, or constipation.
Addiction Treatment: PPL-138 can block relapse in addicted subjects - making it a very promising treatment for addiction.
Treatment of PTSD: PPL-138 reduces stress and other PTSD symptoms - and also dramatically reduces associated alcohol consumption.
Opioids are the most widely prescribed drugs for treatment of moderate to severe pain. However, their use is plagued by serious side effects, including abuse and addiction, severe withdrawal, constipation, respiratory depression, and death from overdose.
All of the leading opioids on the market today like morphine, Oxycodone, Hydrocodone, methadone, fentanyl, etc. – as well as heroin – bind to the Mu receptor in the brain and then aggressively stimulate that receptor. Mu produces potent pain relief, but it also produces a euphoric “high” – which leads to abuse and addiction.
Millions of Americans are seriously addicted to opioids – and it is a devastating addiction. There is a huge unmet medical need to comprehensively address the abuse, addiction, and mortality associated with opioids.
Phoenix Pharma Labs has a portfolio of drugs under development with unique opioid receptor characteristics that do not produce the euphoric “high” that leads to abuse and addiction. These drugs treat moderate to severe acute and chronic pain without the dangerous side effects found in other opioids such as morphine, Oxycodone, Hydrocodone, etc.
We continue to seek complimentary business and investment relationships, out-licensing opportunities and/or co-development opportunities with both domestic and overseas partners as we advance our drug candidates through pre-clinical and clinical trials.
Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.
Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies. He has a proven track record of successfully commercializing various emerging technologies including manufacturing and industrial systems, computer software, marine bioremediation, nanotechnology and life sciences.
Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth.
The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.